medRxiv Preprint Server
June 17, 2026
Danny Nacker, Luise Kalus, Anil K. Seth et al.
preprint
Stroboscopic light stimulation (SLS) is a candidate non-pharmacological intervention that induces transient visual and affective experiences, with potential application in depression. Before efficacy testing, clinical development requires safety, tolerability and feasibility data. We report a staged, single-site programme in adults reporting depressive symptoms. Work Package (WP) 1 tested 11...
medRxiv Preprint Server
May 31, 2026
Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al.
preprint
Background Ketamine has emerged as an effective rapid-acting treatment for treatment-resistant depression (TRD), producing significant antidepressant effects within hours of administration. Given ketamine’s capacity to induce states of heightened neuroplasticity and psychological openness, psychotherapy may represent a meaningful complement to its pharmacological effects — facilitating...
medRxiv Preprint Server
May 31, 2026
Madeline V. Stein, Matt Butler, Sarah Chapman et al.
preprint
Psychedelic drugs are emerging as potentially efficacious tools for treating psychiatric conditions and probing the neural basis of consciousness. Although drug administration context is widely believed to shape psychedelic effects, it remains unclear whether it can independently generate placebo and nocebo effects resembling psychedelic experiences and side effects. In a pre-registered...
medRxiv Preprint Server
May 23, 2026
Lisa Maria Jöbstl, Bente Lubahn, Ebru Kaya et al.
preprint
Background While growing enthusiasm for the therapeutic potential of classic psychedelics has led to a rise in non-clinical use, attention to persisting adverse effects has emerged with delay. A subset of individuals reports persisting complications such as hallucinogen persisting perception disorder (HPPD), depersonalization/derealization disorder (DDD), anxiety and depression. Yet few medical...
medRxiv Preprint Server
May 5, 2026
Tom M. Quinn, Feng Li, Becky Wheeler et al.
preprint
The development of lung-directed therapeutics is limited by poor translational fidelity between preclinical models and early-phase clinical trials. We report a first-in-human Phase 0 intratarget microdosing study demonstrating the feasibility of intrapulmonary delivery and pharmacological interrogation of a novel inflammasome inhibitor. A 100 μg microdose of ADS032, a dual NLRP1/NLRP3...
medRxiv Preprint Server
May 5, 2026
Nicholas C. Borgogna, D. Drew Whittington, Tyler Owen et al.
preprint
Mental illness poses a substantial global burden, yet existing psychotherapies and psychopharmacologies often produce limited outcomes. Psychedelic-assisted therapies have re-emerged as potential transdiagnostic interventions. In particular, 3,4-methylenedioxymethamphetamine–assisted therapy (MDMA-AT) has generated interest for its rapid psychological effects and potential to enhance...
medRxiv Preprint Server
April 28, 2026
Sandeep M. Nayak, Nathan D. Sepeda, Matthew Nielsen Dick et al.
preprint
Background Psilocybin has increasingly been studied as a therapeutic for psychiatric and neurologic conditions, yet comprehensive cardiovascular safety data are limited. Current trials often exclude individuals with blood pressure ≥140/90 mmHg, criteria established conservatively without robust empirical support.
medRxiv Preprint Server
April 23, 2026
Willys Cantenys, Zeynep Yoldas, Luc Masset et al.
preprint
Background Ketamine is a rapid-acting antidepressant that produces acute dissociative symptoms. In routine care, the respective contributions of therapeutic expectations and dissociative symptoms to antidepressant response, and the directionality of their associations with depressive symptom change, remain poorly characterized.
medRxiv Preprint Server
April 23, 2026
Giada Lombardi, Grace Blest‐hopley, Martina Maria Tarantini et al.
preprint
Regular cannabis use has been associated with alterations in reward-related neural processes, yet findings remain inconsistent and the relationship between neural activity and behavioural performance is not fully understood. The present study aimed to characterise neural and behavioural correlates of reward processing in regular cannabis users (CU) compared with matched non-users (NU) using the...
medRxiv Preprint Server
April 19, 2026
Cameron C. Glick, Saad Pirzada, Shaun K.l. Quah et al.
preprint
Background Scalable, low-burden behavioral interventions are needed to address rising subclinical mental health symptoms. However, few randomized controlled trials have evaluated ultra-brief, remotely delivered, meditation using multimodal outcome assessment under real-world conditions.
medRxiv Preprint Server
April 17, 2026
Chiranth Bhagavan, Orwa Dandash, Olivia Carter et al.
preprint
Background Psilocybin is a classic psychedelic that acutely alters brain functional connectivity. These changes are linked to therapeutic doses and subjective effects, with some evidence that changes persist beyond acute drug administration. However, the effects of lower doses on sustained connectivity changes remain unclear.
medRxiv Preprint Server
April 1, 2026
Jiawei Zhu, Zhenfu Wen, Yonghao Cao et al.
preprint
Carsickness impairs comfort and affects a large proportion of the population. However, interventions that provide a therapeutic solution to carsickness have yet to be established. Here we introduce a wearable mindfulness meditation brain–computer interface (MM-BCI) system as a closed-loop training therapy for carsickness. The system records electroencephalographic activity, decodes meditative...
medRxiv Preprint Server
March 31, 2026
Maia Mallevays, Louise Fuet, Michel Danon et al.
1 citation
preprint
Esketamine is a fast-acting antidepressant drug which induces acute psychoactive effects. The most frequent is a dissociative state which seems unrelated to therapeutic efficacy. Other esketamine-induced effects, including psychedelic-like mystical experiences, have been poorly studied in terms of phenomenology and frequency, and may carry specific therapeutic relevance. In this study, we...
medRxiv Preprint Server
March 27, 2026
Brooke L. Sevchik, S. Parker Singleton, Analiese Lahey et al.
preprint
3,4-methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD), generating considerable enthusiasm in the field. However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release,...
medRxiv Preprint Server
February 23, 2026
Fernando A. Wilson, Eric L Garland
preprint
OBJECTIVE Opioid misuse exacts a tremendous toll on society. Mindfulness-Oriented Recovery Enhancement (MORE) is an efficacious treatment for opioid misuse. Yet, the cost-effectiveness of this intervention remains unknown.
medRxiv Preprint Server
January 14, 2026
Gaia Zin, Guy Nagels, Jeroen Van Schependom et al.
preprint
Introduction The balance between excitatory and inhibitory (E/I) neural processes is a fundamental principle of brain function, and its disruption has been implicated in the pathophysiology of multiple sclerosis (MS). In vivo assessment of E/I balance has traditionally relied on electrophysiological measures, and despite the abundance of fMRI data on MS, no fMRI-based technique has so far been...
medRxiv Preprint Server
January 13, 2026
Deniz Yilmaz, Lena Deller, Johanna Spaeth et al.
preprint
When the brain and body misalign, emotional experience and sense of reality can be disrupted. Although such atypical experiences are central to schizophrenia spectrum disorders (SSD), interoception, processing of internal bodily signals, remains poorly understood in individuals with SSD, particularly across subjective, behavioural, and neural domains. We tested whether SSD is associated with...
medRxiv Preprint Server
December 16, 2025
Derek Newman, Charlotte Maschke, George A. Mashour et al.
preprint
Background Propofol exposure can produce heterogenous neural responses, from the expected suppression to transient paradoxical excitation. EEG measures of signal complexity and entropy have emerged as reliable markers of consciousness, but different types of complexity and entropy measures are often conflated. We used Type I and II complexity measures on the Complexity–Entropy Causal Plane...
medRxiv Preprint Server
December 5, 2025
Gabriel Loewinger, Mats J. Stensrud, Sandeep M. Nayak et al.
preprint
In clinical trials for mental health treatments, functional unmasking (unblinding) is a widespread challenge wherein participants become aware of their assigned treatment. Unmasking is especially concerning with psychedelics, due to the near unmistakable acute effects (the “trip”), resulting in uncertainty about whether outcomes following treatment reflect true therapeutic properties of the...
medRxiv Preprint Server
May 26, 2025
Nathan J Wellington, Bonnie L. Quigley, Ana P. Bouças et al.
preprint
Ketamine’s rapid acting symptom relief make it a promising intervention for PTSD. However, the mechanisms driving its long-term efficacy over weeks and months remain poorly understood. This study investigated the short-and long-term impacts on gene expression of a six-week subanesthetic oral ketamine trial in 23 PTSD participants (9 males, 14 females). Peripheral Blood Mononuclear Cells (PBMCs)...
medRxiv Preprint Server
March 21, 2025
Leo R. Silberbauer, Benjamin Eggerstorfer, Paul Michenthaler et al.
1 citation
preprint
Background Ketamine represents a significant advancement in antidepressant therapy, but the commonly used intravenous and intranasal application routes currently limit its availability beyond specialized centers. By contrast, oral ketamine treatment might constitute an alternative that is easy to administer with established safety and efficacy for patients with chronic and severe pain at home.
medRxiv Preprint Server
March 2, 2025
Bonnie L. Quigley, Emerald Orr, Sophie Kafka et al.
preprint
Ketamine has been investigated as a treatment alternative for PTSD for the last 20 years, yet there have been virtually no reports of biological changes or biomarker characterisation related to treatment. To address this significant gap, this study analysed blood samples from 25 participants with PTSD who took part in an open-label 6-week trial of low dose oral ketamine treatment. Serum and...
medRxiv Preprint Server
February 25, 2025
J Cohen, AC Reichelt, R Zamyadi et al.
1 citation
preprint
This detailed case report explores the application of ketamine-assisted psychotherapy (KAP) in the treatment of a male patient in their late 30’s with Generalized Anxiety Disorder (GAD) and depressive symptoms. The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine represents a significant breakthrough in the treatment of mood and anxiety disorders due to its rapid and robust...
medRxiv Preprint Server
November 26, 2024
Bonnie L. Quigley, Adem T. Can, Megan Dutton et al.
1 citation
preprint
Ketamine is being actively investigated as a rapid-acting treatment for many conditions with a stress-related psychopathology, including post-traumatic stress disorder (PTSD). The majority of studies regarding ketamine treatment for PTSD to date (including open-label and randomised control trials) have focused on intravenous (IV) ketamine administration. This administration route has...
medRxiv Preprint Server
September 10, 2024
Kristin L Dawson, Athena May Jean M. Carangan, Jessica Klunder et al.
4 citations
preprint
Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine’s effects on...